SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The 401jk (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and also the 401k. The 401k total holdings are valued at around $12 trillion USD and it is the most popular retirement savings plan in the US. As time passes forevermore true retirement, or as we like to call it real freedom will only become much harder and harder for people to attain.  Through meme fueled laser focus and cyperphunk ideology the 401jK meme retirement fund token and community aim to point out the absurdities of how rigged our current system is, and how only insiders and those with power are starting the benefit from the increased centralization of cryptocurrency.........while also aiming to flip the $12 trillion USD 401k system to achieve freedom before our backs and knees are breaking.

401jK

401JK.X is trending as a satirical take on traditional retirement plans, with the community rallying around its potential as a path to early retirement. The coin is seeing increased attention, driven by an active community and a narrative that resonates with those seeking alternatives to conventional systems. Discussions highlight the coin's limited supply and potential for significant growth within the Solana memecoin market.

The project is a derivative of Fartcoin. The Fartcoin deployer has deployed this token because the President at Bone Fide Wealth tweeted about "A client just called and asked me if there’s going to be a Fartcoin ETF this year." Since the Elon narrative is has been running this one has come to existence. The token is following different narratives like Fartcoin, SPX500 and other big memes following the Trump narrative.

Elon Trump Fart

ETF500.X is trending as the community rallies around potential gains, fueled by discussions of "pumping" the coin and achieving new all-time highs. Some users are focused on accumulating and holding, while others debate whether it's a legitimate opportunity or a "scam." The coin's association with Solana and mentions of meme season are also circulating.

The national debt has increased every year for the past ten years, and interest expenses have remained fairly stable due to low interest rates and the perceived low risk of U.S. government default, according to the U.S. Treasury Fiscal Data. This coin is a parody coin about the debt crises in the US and to highlight various aspects about this crises in a humouros way to the people on solana. $USNDC

UnitedStates National Debt Coin

UnitedStates National Debt Coin ($USNDC.X) is gaining attention, with community members highlighting its strong chart and potential for a pump. Many are emphasizing the importance of buying early via Phantom wallet, noting increased buying pressure and rising liquidity. The coin is also trending alongside UpDog ($UPDOG.X), further fueling community excitement.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics is trending due to anticipation surrounding upcoming data releases for its cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency programs, with the community actively discussing potential trial outcomes and regulatory paths. Recent call option activity and analyst upgrades suggest expectations for a significant upward move, while a lawsuit against AbbVie over alleged intellectual property theft adds another layer of intrigue. Community members are weighing the potential impact of positive data against risks, considering factors like trial design and competitive landscape.

FFFFFFFFFFFFFUUUUUUUUUUUUUUUU

RAGEGUY.X is trending as community members discuss potential for a "V-shape recovery" and highlight a DEX listing they believe could offer significant upside. Some users are pointing to a related ticker, $RAGE.X, suggesting increased activity and whale interest there. Others express concern about the coin's volatility.

Subsquid Network is an innovative decentralized data lake and query engine designed to offer developers performant and permissionless access to data, aiming to build a neutral and open internet rooted in Web3 principles. Secured by ZK proofs, the Subsquid network boasts a modular architecture that enables exceptional scalability and developer convenience optimized for blockchain indexing, dApp development, and analytics.  Subsquid is a response to unscalable and rigid monolithic indexing frameworks that had previously gained popularity and market traction among Web3 developers. Today, these frameworks are struggling to adapt in a rapidly evolving blockchain environment. Additionally, the network serves as a highly efficient and decentralized alternative to centralized infrastructure firms, including large RPC and API providers.

SQD.X is trending amid community excitement and increased buying pressure, with many anticipating a continued surge toward previous highs. Discussions revolve around key resistance levels, potential breakout points, and comparison to similar crypto movements. Some traders are also pointing to its utility as a reason for optimism.

Aster is a next-generation decentralized exchange offering both Perpetual and Spot trading, designed as a one-stop onchain venue for global crypto traders. It features MEV-free, one-click execution in Simple Mode. Pro Mode adds 24/7 stock perpetuals, Hidden Orders, and grid trading, available across BNB Chain, Ethereum, Solana, and Arbitrum.  Its unique edge lies in the ability to offer liquid-staking tokens (asBNB) or yield-generating stablecoins (USDF) as collateral, unlocking unparalleled capital efficiency. Powered by Aster Chain, a high-performance and privacy-focused L1, and backed by YZi Labs, Aster is building the future of DeFi: fast, flexible, and community-first.  At the heart of this ecosystem is the $ASTER token, a core asset that decentralizes governance, drives growth, rewards participation, and supports long-term sustainability.

ASTERION

ASTER.X is trending as traders discuss its potential as a perp DEX, drawing comparisons to similar platforms and anticipating increased accessibility with BTC deposits. Community members are weighing in on technical analysis, identifying key price levels, and debating short-term trading strategies. The coin's circulating supply and potential for yield are also hot topics.

DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

DaVita Inc

DaVita is trending amid discussions about potential trade flow and upcoming infection data from CMS, with some traders targeting call options.  The community is also focused on the Kidney Care Access Protection Act (S.2730) and its potential impact on dialysis patients and companies like DaVita. Additionally, some are advocating for the adoption of DefenCath at DaVita facilities, citing its life-saving benefits and current non-availability at DaVita.

Jupiter is a cryptocurrency exchange platform on the Solana blockchain, offering features such as token swapping, limit orders, dollar-cost averaging, and a bridge for asset transfers to Solana. It provides users with tools to find the best trading prices and includes a beta version for perpetual futures trading. Jupiter finds the best price route for your swap by aggregating all the major liquidity sources on Solana.

Jupiter

Jupiter ($JUP.X) is trending due to excitement surrounding its association with $UPDOG.X, a Solana-based meme coin, and users are actively swapping $SOL.X for $UPDOG.X on the Jupiter platform. The community highlights $UPDOG.X's presence on Jupiter's strict list and its established history on the Solana network, signaling growing confidence. Community members express strong bullish sentiment, viewing $UPDOG.X as a promising project within the Solana ecosystem.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Are Medical Stocks Lagging  Argenx (ARGX) This Year?

Here is how argenex SE (ARGX) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.

KMDA or ARGX: Which Is the Better Value Stock Right Now?

KMDA vs. ARGX: Which Stock Is the Better Value Option?

15 names that Morgan Stanley’s analysts expect to move meaningfully on earnings

Investing.com -- Morgan Stanley expects a “normal” earnings beat rate for the second quarter, with S&P 500 EPS growth forecast at 5% year-over-year and sales up 4%.

EXEL vs. ARGX: Which Stock Should Value Investors Buy Now?

EXEL vs. ARGX: Which Stock Is the Better Value Option?

Deutsche Bank bearish on European pharma stocks into Q2 amid political headwinds

Investing.com -- Deutsche Bank has made several rating and target price adjustments across the European pharmaceuticals space ahead of second-quarter earnings, flagging continued weakness in the sector and potential opportunities in select names.

Biogen shares slipped on Monday after the company said it expects to take a $46 million charge in the second quarter related to R&amp;D deals and milestone payments.&nbsp;The expense is set to shave&nbsp;off about $0.26 off its per-share earnings, both on a GAAP and adjusted basis.The update adds to investor caution following the FDA’s recent signal report published on June 30, which named Biogen’s Alzheimer’s treatment Leqembi as one of several drugs flagged for potential post-marketing safety concerns.&nbsp;The report, compiled from the FDA’s FAERS database, represents a push for increased transparency around adverse event reporting.Analysts at RBC Capital said they do not anticipate major regulatory fallout, noting that the data was already publicly available and the risks broadly acknowledged.&nbsp;However, they said the FDA’s move could still create some sentiment overhang for Biogen and other named firms, including Sarepta, Alkermes, Biohaven, Xenon, and Argenx.<a href="https://stocktwits.com/symbol/BIIB">Biogen’s</a> newly itemized R&amp;D charges follow its Q1 decision to present such costs as a separate line item on its income statement.&nbsp;The company stated that these typically include expenses from licensing deals and asset acquisitions, which are accounted for as in-process research and development.Meanwhile, Biogen is advancing its drug pipeline, beginning a Phase 3 study with felzartamab, which can treat a kidney condition known as primary membranous nephropathy.The trial, dubbed Prominent, began dosing patients late last month and will enroll about 180 adults.On Stocktwits, retail sentiment for Biogen was ‘bullish’ amid ‘low’ message volume.Biogen’s stock has declined 13.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration the logo of Biogen is seen on a smartphone with the FDA logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)  

Biogen Shares Slip After $46M Research Charge Hits Quarterly Profit

The company anticipates a research expense in Q2 associated with milestone and licensing payments, which will impact both GAAP and non-GAAP earnings per share.

Equity

EXEL or ARGX: Which Is the Better Value Stock Right Now?

Nasdaq-listed shares of argenx SE (ARGX) rose 2% by Friday afternoon after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://argenx.com/news/2024/argenx-announces-european-commission-approval-of-vyvgart--efgart">announced</a> that the European Commission approved its VYVGART 1,000 mg subcutaneous (SC) injection in the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP).CIDP is a rare and often progressive autoimmune disease of the peripheral nervous system. Patients with CIPD experience a range of mobility and sensory issues, including trouble standing from a seated position, pain and fatigue, and frequent tripping or falling.The European Commission approved the subcutaneous injection as a monotherapy for patients with the disease who have received prior treatment with corticosteroids or immunoglobulins.The EC approval will apply to all 27 European Union Member States, as well as to Iceland, Liechtenstein, and Norway.VYVGART for SC injection is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional. The company stated that it is “working closely” with local regulatory authorities to ensure patients can access the treatment as soon as possible.The approval is based on a clinical trial that demonstrated 66.5% of patients treated with VYVGART SC showed evidence of clinical improvement, including improvements in mobility, function, and strength. The study also revealed a 61% reduction in the risk of relapse compared to the placebo.This regulatory approval marks the second for VYVGART SC in Europe, which first received approval as an add-on to standard therapy for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.On Stocktwits, retail sentiment around argenx remained within ‘bullish’ territory over the past 24 hours while message volume remained ‘normal’.<figure class="image"><img style="aspect-ratio:631/68;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_20_at_2_09_51_PM_png_2b09c4d552.webp" alt="ARGX's Sentiment Meter and Message Volume as of 2:10 p.m. ET on June 20, 2025 | Source: Stocktwits" width="631" height="68"><figcaption>ARGX's Sentiment Meter and Message Volume as of 2:10 p.m. ET on June 20, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/ARGX">ARGX stock</a> is down by 12% this year but has gained over 40% in the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/meta-considered-perplexity-acquisition-before-14-3-b-scale-ai-deal/chlxqohRRPz">Meta Reportedly Considered Perplexity Acquisition Before $14.3B Scale AI Deal</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration an argenx SE logo seen displayed on a smartphone. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Argenx Gets European Commission Approval For Drug To Treat Rare Autoimmune Disease, But Stock Fails To Garner Retail Attention

VYVGART for SC injection is available in vials or prefilled syringes and can be administered by a patient, caregiver, or healthcare professional.

Argenx (ARGX) Upgraded to Buy: Here's Why

argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.

ARGX
Argenx

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ARGX News

ARGX Argenx